NanoViricides Inc. (NYSE American: NNVC) announced its participation in the Spartan Capital Investor Conference 2025, where the clinical-stage company will present its pipeline of broad-spectrum antiviral drugs designed to prevent viral escape. The presentation scheduled for November 3, 2025, at 9:45 a.m. ET in New York City represents a significant opportunity for investors to understand the company's novel approach to antiviral therapy.
The company's lead drug candidate, NV-387, represents a potential breakthrough in antiviral treatment with planned development for respiratory syncytial virus (RSV), COVID-19, Long COVID, influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. This broad-spectrum capability is particularly important given the ongoing challenges of emerging viral threats and the limitations of current antiviral treatments that often target specific viruses.
NanoViricides' second advanced candidate, NV-HHV-1, targets shingles treatment, addressing another significant viral disease burden. The company's technology platform, based on intellectual property from TheraCour Pharma Inc., enables the creation of special purpose nanomaterials for antiviral therapy. Additional details about the company's technology and programs are available at https://www.nanoviricides.com.
The company's development pipeline extends beyond its lead candidates to include drugs against oral and genital herpes, viral eye diseases including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus. This extensive portfolio demonstrates the potential breadth of application for the nanoviricide technology across multiple viral threats that continue to challenge global public health systems.
NanoViricides holds exclusive worldwide perpetual licenses for several viral disease treatments through its relationship with TheraCour, which licenses the underlying nanomedicine technology from AllExcel. The licensed fields include Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B and C viruses, Rabies, Herpes Simplex Virus, Varicella-Zoster Virus, Influenza, Asian Bird Flu, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The company intends to pursue additional licenses for RSV, Poxviruses, and Enteroviruses pending successful initial research.
Currently, NanoViricides is focused on advancing NV-387 into Phase II human clinical trials, though the company notes it cannot project exact dates for filing Investigational New Drug applications due to dependence on external collaborators and consultants. The company emphasizes the inherent risks of drug development, acknowledging that the path to pharmaceutical product approval is extremely lengthy and requires substantial capital, with no assurance that any candidate will demonstrate sufficient effectiveness and safety for human clinical development.
Investors seeking additional information about NanoViricides can access the latest news and updates in the company's newsroom at https://ibn.fm/NNVC. The company's presentation at the Spartan Capital Investor Conference represents an important milestone in communicating its progress and potential to the investment community while highlighting the broader significance of developing novel antiviral approaches in an era of increasing viral threats.
